Benitec Biopharma (BNTC) Liabilities and Shareholders Equity (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $190.7 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 141.16% year-over-year to $190.7 million; the trailing twelve-month figure through Dec 2025 stood at $386.3 million (up 79.63% YoY), and the FY2025 full-year result was $99.6 million, up 90.75% from the prior year.
• Liabilities and Shareholders Equity advanced to $190.7 million in Q4 2025, from $96.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $190.7 million in Q4 2025 to a low of $4.5 million in Q2 2023.
• A 5-year average of $40.8 million and a median of $18.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity plunged 72.06% in 2022 and soared 1069.58% in 2024, its largest moves.
• Tracing BNTC's Liabilities and Shareholders Equity over 5 years: stood at $14.0 million in 2021, then decreased by 15.05% to $11.9 million in 2022, then surged by 79.36% to $21.4 million in 2023, then jumped by 270.29% to $79.1 million in 2024, then soared by 141.16% to $190.7 million in 2025.
• Business Quant data shows BNTC's Liabilities and Shareholders Equity at $190.7 million in Q4 2025, $96.0 million in Q3 2025, and $99.6 million in Q2 2025.